Kao Corporation: Regarding the Nomination of Director Candidates for Our Company
Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges.
Kao adheres to a robust selection process to ensure an optimal composition of the Board of Directors. As announced in the December 12 press release, this fiscal year, the selection of candidates was deliberated over a period of more than six months by the Board of Directors and the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members. The candidates for Directors and Audit & Supervisory Board Members were announced on December 2 to coincide with the announcement of the new Executive Officer structure.
The announced individuals are proposed candidates and do not preclude proposals from other shareholders. Following our company's selection process, we are currently conducting the appropriate evaluation for the director candidates proposed by certain shareholders.
Kao will remain committed to ensuring fair disclosure of information to all stakeholders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241218200830/en/
Contacts
Media inquiries should be directed to:
Public Relations
Kao Corporation
corporate_pr@kao.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces $40,000 Academic Award to Empower the Next Generation of Supply Chain Innovators19.12.2024 13:00:00 CET | Press Release
In celebration of its 40th anniversary, Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced a $40,000 academic award to help students looking to pursue careers in supply chain. Kinaxis is strengthening its partnerships with Texas Christian University, University of Toronto and Carleton University to provide each institution with a portion of the award to go towards helping students currently enrolled in supply chain, AI or computer science programs to shape the future of supply chains. The Kinaxis academic award comes at a time when the need for supply chain talent is growing. As validated by a recent IDC survey sponsored by Kinaxis, over 32% of global supply chain leaders stating the ability to attract and retain top talent with the right skills is a top concern for business continuity. “As supply chains increase in scale and complexity, cultivating the next generation of leaders becomes essential,” said Gelu Ticala, chief technology officer a
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy19.12.2024 12:00:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). Efficacy Results The study’s primary endpoint was a within-group change from baseline in the weekly average of daily leg pain intensity on the NPRS at Week 12. This 11-point scale ranges from 0 (no pain) to 10 (worst pain imaginable). The suzetrigine arm showed a statistically significant and clinically meaningful within-group reduction from baseline in pain with a mean change in NPRS at Week 12 of -2.02. The study also included a placebo reference arm which showed a similar within-group reduction from baseline in pain with a mean change in NPRS at Week 12 of -1.98. The study was not designed nor pow
Ukraine Conflict Impacting Nordics Cloud Adoption19.12.2024 10:00:00 CET | Press Release
The conflict in Ukraine has intensified supply chain disruptions, affecting IT investments across the Nordics, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2024 ISG Provider Lens™ Multi Public Cloud Services report for the Nordics finds companies in the region are grappling with rising IT costs and a shortage of skilled labor, which is directly impacting their cloud adoption strategies. As a result, many organizations are focusing their investments on projects the deliver immediate business value, while deferring less critical initiatives. This trend, ISG says, underscores the need for agile and efficient cloud solutions that can adapt to evolving market conditions. The demand for hybrid and multicloud solutions is rising, driven by the need for robust digital infrastructure and low-cost energy and reduced concerns about security and vendor lock-in. “There’s a supportive
Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA19.12.2024 09:00:00 CET | Press Release
Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULDOSA (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, IMULDOSA is now fully authorized to enter the global market. IMULDOSA, a biosimilar referencing Stelara of Janssen Pharmaceuticals, is indicated for treating inflammatory diseases, including plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Stelara, with its active ingredient ustekinumab, is among the top-grossing biologics worldwide, generating $20.323 billion in cumulative global sales in 2023, according to IQVIA. The development of IMULDOSA bega
ASTRA 1P Starts Delivering Content Across Europe19.12.2024 08:50:00 CET | Press Release
SES announced today that ASTRA 1P, the company's most advanced satellite positioned at 19.2 degrees East, has completed comprehensive testing and is now fully operational. Following its successful in-orbit raising and performance testing, ASTRA 1P will now start serving public and private broadcasters, sports organisations and content owners, achieving another milestone in SES’s commitment to delivering high-quality broadcast services to the widest audience possible. ASTRA 1P is SES’s most powerful wide-beam satellite to broadcast from the 19.2 degrees East TV neighbourhood. Equipped with 80 transponders, ASTRA 1P can support hundreds of HD TV channels, ensuring the delivery of superior image quality to viewers across key European TV markets. “With ASTRA 1P now fully operational, we are setting a new standard for satellite broadcasting in Europe,” said Milton Torres, CTO of SES. “This new offering will enhance our ability to deliver premium content with superior reliability and image q
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom